II 

118TH CONGRESS 

2D SESSION S. 5206 

To require a report on foreign investment in the pharmaceutical industry 

of the United States. 

IN THE SENATE OF THE UNITED STATES 

SEPTEMBER 25, 2024 

Ms. WARREN (for herself and Mr. RUBIO) introduced the following bill; which 

was read twice and referred to the Committee on Banking, Housing, and 

Urban Affairs 

A BILL 

To require a report on foreign investment in the 

pharmaceutical industry of the United States. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘United States Pharma5 ceutical Supply Chain Review Act’’. 

6 SEC. 2. REPORT ON FOREIGN INVESTMENT IN PHARMA7 CEUTICAL INDUSTRY. 

8 (a) IN GENERAL.—Not later than 1 year after the 

9 date of the enactment of this Act, and annually thereafter, 

10 the Federal Trade Commission (in this section referred 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•S 5206 IS

1 to as the ‘‘Commission’’), in consultation with the Sec2 retary of Commerce, shall submit to the appropriate con3 gressional committees, the Secretary of Health and 

4 Human Services, the Committee on Foreign Investment 

5 in the United States, and the Commissioner of Food and 

6 Drugs, a report on foreign investment in the pharma7 ceutical industry of the United States. 

8 (b) ELEMENTS.—The report required by subsection 

9 (a) shall include an assessment of— 

10 (1) the supply chain of the pharmaceutical in11 dustry of the United States and the effect of con12 centration and reliance on foreign manufacturing 

13 within that industry; 

14 (2) the effect of foreign investment in the phar15 maceutical industry of the United States on domes16 tic capacity to produce drugs and active and inactive 

17 ingredients of drugs; 

18 (3) the effect of foreign investment in tech19 nologies or other products for sequencing or storage 

20 of DNA, including genome and exome analysis, in 

21 the United States, including the effect of such in22 vestment on the capacity to sequence or store DNA 

23 in the United States; and 

24 (4) the effect of pharmaceutical manufacturers 

25 in the United States relocating manufacturing faciliVerDate Sep 11 2014 19:44 Oct 09, 2024 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S5206.IS S5206

ssavage on LAPJG3WLY3PROD with BILLS
3 

•S 5206 IS

1 ties to other countries on domestic capacity to 

2 produce drugs and active and inactive ingredients of 

3 drugs. 

4 (c) AUTHORITY.—The Commission shall have author5 ity under section 6 of the Federal Trade Commission Act 

6 (15 U.S.C. 46) to conduct the studies required to prepare 

7 the report required by subsection (a). 

8 (d) PUBLICATION.—The Commission shall publish an 

9 unclassified summary of the report required by subsection 

10 (a) on a publicly available internet website of the Commis11 sion. 

12 (e) APPROPRIATE CONGRESSIONAL COMMITTEES DE13 FINED.—In this section, the term ‘‘appropriate congres14 sional committees’’ means— 

15 (1) the Committee on Banking, Housing, and 

16 Urban Affairs, the Committee on Health, Education, 

17 Labor, and Pensions, the Committee on Armed 

18 Services, the Committee on Foreign Relations, the 

19 Committee on Commerce, Science, and Transpor20 tation, and the Committee on Appropriations of the 

21 Senate; and 

22 (2) the Committee on Financial Services, the 

23 Committee on Energy and Commerce, the Com24 mittee on Armed Services, the Committee on ForVerDate Sep 11 2014 19:44 Oct 09, 2024 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S5206.IS S5206

ssavage on LAPJG3WLY3PROD with BILLS
4 

•S 5206 IS

1 eign Affairs, and the Committee on Appropriations 

2 of the House of Representatives. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS